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Background: 2,4-Dinitrophenol (DNP) poses serious health-risks to humans. The aims of this three-stage
multidisciplinary project were, for the first time, to assess the risks to the general public from fraudulent sale of
or adulteration/contamination with DNP; and to investigate motives, reasons and risk-management among
DNP-user bodybuilders and avid exercisers.
Methods: Using multiple search-engines and guidance for Internet research, online retailers and bodybuilding
forums/blogs were systematically explored for availability of DNP, advice offered on DNP use and user profiles.
Ninety-eight pre-workout and weight-loss supplements were purchased and analysed for DNP using liquid-
chromatography-mass-spectrometry. Psychosocial variables were captured in an international sample of 35 DNP
users (26.06 ± 6.10 years, 94.3 % male) with an anonymous, semi-qualitative self-reported survey.
Results: Although an industrial chemical, evidence from the Internet showed that DNP is sold ‘as is’, in capsules or
tablets to suit human consumption, and is used ‘uncut’. Analytical results confirmed that DNP is not on the supplement
market disguised under fictitious supplement names, but infrequently was present as contaminant in some supplements
(14/98) at low concentration (<100mcg/kg). Users make conscious and ‘informed’ decisions about DNP; are well-prepared
for the side-effects and show nonchalant attitude toward self-experimentation with DNP. Steps are often taken to ensure
that DNP is genuine. Personal experience with performance- and appearance enhancing substances appears to be a
gateway to DNP. Advice on DNP and experiences are shared online. The significant discrepancy between the normative
perception and the actual visibility suggests that DNP use is-contrary to the Internet accounts-a highly concealed and
lonesome activity in real life. Positive experiences with the expected weight-loss prevail over the negative experiences
from side effects (all but two users considered using DNP again) and help with using DNP safely is considered preferable
over scare-tactics.
Conclusion: Legislation banning DNP sale for human consumption protects the general public but DNP is sold ‘as is’ and
used ‘uncut’ by determined users who are not dissuaded from experimenting with DNP based on health threats.
Further research with stakeholders’ active participation is imperative for targeted, proactive public health policies and
harm-reduction measures for DNP, and other illicit supplements.
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Fig. 1 Chemical structure of 2,4 dinitrophenol and sodium
dinitrophenolate (PubChem Open Chemistry Database)
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Epidemics of obesity have been documented in most
developed countries [1–3], thus finding efficient, but
safe, pharmacological aids to weight loss is in the focus
of the involved healthcare systems and the holy grail of
obesity research. However, agents that are effective for
weight-loss often have severe side effects [4]. Believing
that freely-available supplements are not harmful, par-
ticularly when from a natural source, people often turn
to herbal dietary supplements that promise weight loss
by boosting metabolism and/or suppressing appetite.
Nonetheless, commercially-available dietary supplements
with weight loss claims have long been suspected for
contamination with booster agents [5–7] and thus it was
a conceivable assumption that DNP could be used as a
booster agent in supplements sold as natural or herbal
weigh loss aids.
From the public health point of view, it is concerning
that hazards from the past (e.g., weight loss medications
that have been stopped decades ago) seem to be a
returning feature of today’s off-street supplement mar-
ket, mainly through retail networks that fall outside
standard safety regulations: the Internet [8]. One such
drug category is the so called “rainbow diet pills”, repre-
senting an array of potent combinations of prescription
medications, that are prohibited in medical practice but
nonetheless available in disguise as herbal diet pills [9].
Another drug that recently returned to the underground
weight-loss product market is 2,4-Dinitrophenol (DNP).
DNP is a manufactured odourless yellow chemical that
does not occur naturally in the environment. It was used
in medical practice until the late 1930s to treat obesity
and was subsequently withdrawn owing to its severe tox-
icity [10]. However, industrial uses of DNP as a dye,
wood preserver, herbicide and film-developer have
remained in place over the years. Recently, DNP resur-
faced as a weight loss product in the supplement market
as Sulfo/Solfo Black, Nitro Kleenup or Caswell No.392
[11], but it also can be sold on the Internet or listed
among the ingredients as Aldifen, Chemox, Nitophen,
Dinofan, Dinosan, Dnoc, Osmotox-, Fenoxyl-, or Terto-
sulphur PRB. In parallel with the re-appearance of DNP
as a weight-loss promoting agent, clinical presentations
with DNP toxicity increased with associated high mor-
tality worldwide [12–14].
To protect the public, the Food Standards Agency
(FSA) issued a warning against health risks from poten-
tial DNP contamination of supplements to healthy indi-
viduals [15, 16]. Subsequently, the FSA took proactive
steps to reduce the availability of DNP through Internet
sales to UK customers [16, 17] and to ensure that DNP
is not sold in disguise under fantasy supplement names.
This project is part of the Agency’s effort to protect the
general public from direct or inadvertent exposure toDNP at harmful concentrations; and the paper presents
the results from the work conducted to this effect in
collaboration between the FSA, local authorities, police
and academic researchers between 2013 and 2015.
Counterbalancing the efforts of regulatory bodies, a
culture exists among bodybuilders that encourages and
provides advice for DNP use. Other than bodybuilders at
risk groups are comprised of adolescents, extreme
dieters and those who are suffering from an eating dis-
order, people with drug abuse history and athletes will-
ing to experiment with dangerous chemicals [18–20]. It
is important that health care professionals in frequent
contact with these groups are cognisant about DNP-
related risks and are well-prepared to recognise the pos-
sible signs and risk factors (i.e., desire to lose a signifi-
cant amount of weight fast or to achieve extremely low
body fat %) for early intervention. Equally, regulatory
bodies and policy makers need to consider harm-
reduction measures along with prevention through con-
trolling access and warning against DNP based on risks
to health.
DNP as a weight-loss agent
Although not licensed for human consumption, DNP
(Fig. 1a) and DNP crystal form (Fig. 1b) are used by
bodybuilders and extreme dieters for their fat burning
properties through inhibiting efficient energy (ATP) pro-
duction in cells. Through uncoupling mitochondrial oxi-
dative phosphorylation by facilitating proton transport
across the mitochondrial membrane, DNP leads to rapid
consumption of energy without generating ATP and
consequently, to increased fat metabolism [11, 12, 21].
However, the weight-loss effect comes with serious, and
in some cases potentially fatal, adverse side effects,
namely hyperthermia (the leading cause of fatality with
acute DNP toxicity) and cardiac arrest, but also diaphor-
esis, tachycardia, tachypnea, skin toxicity, Fourier’s gan-
grene and cataracts with low dose chronic exposure
[10–14, 22, 23]. The proposed mechanism of DNP
induced toxicity suggests the activation of ATP-sensitive
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of exposure in DNP-related illnesses and deaths range
between (1 to 46 mg/kg/day and 3 to 46 mg/kg/day, re-
spectively). Taken together, the evidence suggests that
there is no universal safe/danger zone with DNP. People
who are not sensitive to DNP can tolerate a higher dose
and/or longer exposure but the same dose is harmful to
those with high sensitivity [26].
Controlling DNP sales and consumption
Because DNP appears to be mostly obtained through
mail order, controlling this problem from the regulatory
point of view is a very difficult task. Under the Sale of
Goods Act 1979, there are strict codes which sellers and
retailers must abide by: the goods they sell must be as
described, of satisfactory quality and fit for purpose. In
2013, the sale of DNP as a fat burner in the UK was
made illegal due to health concerns [27–29]. As a result,
those wishing to use the drug turned to the Internet and
other sources. This makes regulation much more diffi-
cult as people have no or very limited legal or other
recourse if the products are not effective or prove to be
harmful [30], unless there are agreements to uphold the
UK Law at the point of sale. As with online pharmacies
[31], one key challenge in any country’s regulatory effort
is the off-shore location, anonymity and fast-changing
nature of Internet retail sites. Although DNP as a fat
burner falls under similar regulation worldwide, it can
be legally obtained for industrial use as long as it is
clearly not intended for human consumption (i.e., not in
capsules or tablets). This latter aspect makes controlling
human consumption of DNP similar to the situation
with legal highs [32, 33]. In both cases, the substance and
advice on use are easily available through the Internet,
where retailers and users are perceived as authoritative
sources for information. Thus for effective prevention, it is
imperative to focus on the users’ side with the view of
developing an understanding of the underlying motiva-
tions and reasons for people’s willingness to take risks
with uncut DNP.
With the persistent supply and popularity of DNP
among bodybuilders and dieters, regulatory efforts to
prevent DNP use are undermined by readily available
retail options on the Internet. One alternative approach
to mitigate health risks people willingly take with
unknown, unlicensed and potentially dangerous sub-
stances is to devise end-user-centred, proactive public
health policies. In order to do this, it is important to
understand the factors that affect an individual’s willing-
ness to take the drug after acknowledgement of the
adverse side effects. Information on how and what
people think about taking a risk with DNP for effective
weight loss is mostly limited to the Internet accounts of
users and those who are actively interested in DNP andseeking information though online forums and discussion
boards. Apart from the Internet, one recent study in the
scientific literature explored young adults’ willingness to
take hypothetical risks with DNP for the desired result in
weight reduction [34]. The results showed that vulnerabil-
ity to DNP-risk was linked to having past experience with
weight loss products and the magnitude of desired
weight-loss. Albeit informative, and the first study to ex-
plore psychosocial factors relating to DNP-risk, the results
were limited by the hypothetical nature of the study. In-
vestigating psychosocial factors among those who are or
have been taking DNP is vital to develop good under-
standing of the driving forces behind this specific health
risk taking. The present study advances this knowledge by
investigating-for the first time–the thought processes
about DNP use among admitted users.
Aims and objectives
The initial aims of the project were to assess whether
regulatory efforts to prohibit DNP sale as a fat-burner
agent have been effective and to ensure DNP is not
available on the market in disguise, under some fictitious
names as supplements to the public. Additionally, for the
first time, the study looked at reasons and expectations
associated with DNP from the users' point of view to
inform effective prevention and harm reduction.
Thus the objectives of this multi-stage multidisciplin-
ary study were:
(Study 1) to explore the online retailers and bodybuild-
ing forums/blogs for availability of DNP to guide the
sampling strategy in Study 2 by identifying bodybuilding
supplements that may be DNP in disguise, may contain
DNP as a booster ingredient (spiking) or prone to DNP
contamination owing to poor quality management; and
to inform Study 3 through personal accounts of experi-
ences and informal advice given on how to use DNP and
whether advice includes warning against DNP.
(Study 2) to investigate the level of risk from potential
fraudulent sales or through adulteration/contamination
in weight-loss promoter supplements; and
(Study 3) to examine DNP users’ motives and reasons
for, attitudes about, normative perceptions and visibility
of DNP use; along with purchase routes, experiences
and risk-management practices with DNP.
Methods
The study consisted of three distinct phases. Study 1
investigated the Internet for the availability of DNP and
advice on use. Study 2 focused on potential contam-
ination or adulteration of bodybuilding supplements
with DNP. Study 3 explored motivations, reasons, expec-
tations and risk-management with DNP in a small sam-
ple of users. The flowchart of the research process is
depicted in Fig. 2.
Fig. 2 Flowchart of the research process depicting the three distinct
phases of systematic Internet search (September - December, 2013),
supplement sampling and screening (January - July, 2014) and survey
study (December 2014 - August 2015). Internet sites were re-checked
in March 2015 with the list revised in August 2015
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internet
Informed by the research protocols for Internet research
[35–37], the Internet search was conducted using the
combination of “DNP AND bodybuilding”, “DNP AND
sale OR retail OR buy” and “DNP AND fat burner OR
weight loss” using two general global search engines Bing
(https://www.bing.com/) and DuckDuckGo (https://www.
DuckDuckGo.com), along with a meta-search engine
“dogpile” (http://www.dogpile.com) which combines Goo-
gle, Yahoo! and Yandex. Hits included into the database
were limited to those available in English. Newspaper arti-
cles, YouTube videos and announcements posted on offi-
cial websites of the regulatory bodies were excluded.
Online retail sites were screened for whether DNP is
offered ‘uncut’ or as an ingredient in supplements. Infor-
mation recorded on these retail sites included formulation,
recommended dosage, health warning (if any) and pur-
chase options. For the forums and blogs, the hits were
read in order and information on dose, cycle, diet,
concomitant supplements/substances and reasons for use
were noted.
Information available through both the retail sites
and the bodybuilding forums on DNP was read in
order of appearance of the sites on the search results
until the harvested information was saturated (i.e., no
new entry could be made). As the main aim of the
Internet search phase of the study was to gather infor-
mation to inform the subsequent studies (2 and 3), the
focus of this phase was constrained to seven parame-
ters, namely (1) availability, (2) formulation, (3) dosage,
(4) cycle, (5) advice on use, including diet and co-
supplementation and (6) health warnings (if any) and
(7) reasons for use. When a supplement was identified
as having potential for containing DNP, it was included
in the supplement sample pool. To capture the dynam-
ics of the supply side, websites identified initially werechecked again at the end of the project, covering at
least 12 months in between.
Study 2: Screening bodybuilding supplements for DNP
Primary target products were dietary supplement, and
specifically fat burners, that are marketed for performance
enhancing and body-building, in all forms-including
capsules, tablets, pills, powders and liquid forms. Protein
shakes which may supplement fitness–particularly those
with a long list of ingredients not just a protein were
included. Meal replacements such as Slim Fast, Atkins,
Slimsticks were excluded.
Sampling
Altogether, samples were procured from high-street out-
lets, gyms and from the Internet. Because Study 1 was
part of an intelligence gathering project to assess com-
pliance with current UK legislation for labelling [38],
sample collection was conducted by Local Authority
Enforcement Teams across England following an infor-
mal procedure for sampling and for the level of informa-
tion recorded. Efforts were made to avoid duplication as
much as possible, but duplicate samples were tested
where received. Regarding supplement sources, Local
Authority Enforcement Teams were instructed to
exclude Internet retailers because these samples were
obtained separately by the Hampshire Scientific Service.
No specific exclusion/inclusion criteria were set for
retailers because the focus of the study was on the
potentially contaminated and/or adulterated products,
not on retail outlets, but it was assumed that the likeli-
hood of finding contaminated/adulterated bodybuilding
supplement with DNP is higher in ‘less prominent’ re-
tailers (i.e., independent stores, small franchise chains)
owing to the limited resources available for quality
assurance. Samples were securely placed in plastic con-
tainers to avoid leakage and catalogued using a unique
alphanumerical identification code. There were no specific
storage and transport requirements prior to analysis.
In addition, as part of the Health Weeks initiative
(which is an annual event in February/March that raises
wellbeing awareness and highlights the services that the
university and the local community offer to support
healthy lifestyles) students and patrons of a commercially-
run gym located on a university campus were invited to
submit an anonymous sample of the fat burner supple-
ments they were using for free testing. Participants were
instructed to place the sample into a dedicated, lockable
metal box which was secured to the wall at the gym recep-
tion. Samples submitted via this method were accompan-
ied by a brief questionnaire which asked participants to
provide information on brand name and purchase location
(at the same level of detail as for samples purchased from
high street/Internet retailers). The information form also
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rienced (if any), reasons for using fat burners (e.g., as
part of a fitness regime; for sustained weight manage-
ment; as a quick start to lose weight/to lose weight for a
specific occasion (e.g., competition, social event, etc.) and
other) source of information consulted about fat
burners (“What information source did you consult
before you decided to use the product?” with answer
options of product label; scientific publications; com-
pany website; retail shop information/leaflet; retail shop
assistant; online retail product information; website for-
ums and discussion boards; healthcare professional;
athletic trainer; friend; and other). The level of concern
about the safety of DNP was rated on a 10-point scale
with 1 = not concerned at all and 10 = very concerned.
Participants were provided with the FSA 2013 state-
ment on the danger of DNP [16] prior to their agree-
ment to participate by donating a sample consisting of
at least one daily dose in a sealed envelope and com-
pleting the short information form. One sample com-
prised of one unit of supplement (i.e., one tub of
powdered supplement, one blister pack/pot of tablets,
ideally a minimum of 5 g), complete with full labelling and
usage instructions.
Where available, each sample was accompanied by
photocopies of the original packaging and product
labels. In addition, information available for these sam-
ples included the purchase location (county and whether
it was high street vs. Internet retailer). These data, along
with the semi-quantitative analytical results were entered
into an Excel spreadsheet and processed using descrip-
tive statistics and presented as bar charts.
Chemical analysis
For this phase of the project, the chemical analysis
focused on screening the supplement samples for DNP
using a liquid-chromatography-mass-spectrometry (LC-
MS/MS) method which was developed in house. The
LC–MS/MS system comprised of a 1260 infinity LC sys-
tem (Agilent Technologies UK) with 1290 infinity
thermo-stated autosampler, degasser, binary pump and
column heater; coupled to a 6430 triple quadrupole
mass spectrometer (Agilent Technologies UK). The ball
mill used for sample preparation was Fritsch P23 mini
ball mill, Germany. Further details of the method are
provided in Additional file 1: DNP method development
for semi-quantitative screening.
Study 3: Investigating personal experiences with DNP
among users
Theoretical framework
The main foci of the survey were on reasons for using
DNP, along with personal experiences and satisfac-
tion with the results and intention to use DNP again.Behavioural reasoning [39] offered a suitable framework
through the exploration of reasons that explain planned,
current and past behaviours. In behavioural models, it is
always an interesting question how far (or near) objective
data support the perception on which reasons are formed
(e.g., perceived safety of DNP, particularly when one
person’s ‘safe dose/regime’ is not transferable to another).
Notwithstanding, behavioural reasoning was used as a
loose theoretical framework because it offers a practical
insight into motivational mechanisms for taking risks with
DNP. At this early stage of researching DNP-related be-
haviour and decisions, we did not set out to test a specific
behavioural reasoning model. Rather, we aimed to ex-
plore–using a mix of quantitative and qualitative data–
how users think about DNP to inform future research en-
deavours. The advantage of looking at DNP through rea-
soning is-similarly to other substances in the functional
drug category [40]-that reasons incorporate pro/con
explanations, cost/benefit rationalisation and situational
facilitators/constraints and exert both indirect (through
contributing to norms, attitudes and perceived control)
and direct influence on behavioural intentions [39].
Sampling
Participants were recruited through Internet-based, English
speaking discussion boards. The inclusion criteria were
having personal experiences (current or recent) with
DNP and willingness to disclose related information
through the anonymous survey. Recruitment was done
through posting a link to the survey along with a brief
description of the study on discussion boards which
allowed us to advertise this study among the members.
We also asked participants and discussion board mem-
bers to promote this study among their peers.
The final sample consisted of 33 males and 2 females
with mean age of 26.06 ± 6.10 years (age range: 18–45
years). Owing to the worldwide reach of the Internet,
participants were from the United Kingdom (n = 15),
the United States (n = 13), Canada (n = 4), followed by
Ireland and Panama (n = 1 each). The highest propor-
tion in the sample was White/Caucasian (n = 25),
followed by Hispanic/Latino/South American (n = 4),
Black or African American and Asian/Pacific Islander
(n = 2 each) and Arab (n = 2).
Measures
Informed choice in the health context is defined by
meeting three conditions (being based on relevant
knowledge, consistent with the values of the person and
behaviourally implemented); and theorised that its
extent is said to be assessed by knowledge about and at-
titudes toward the behavioural choice [41]. In the
present study, a semi-qualitative, self-reported survey
was administered using a closed online survey platform
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with five direct statements (response recorded on a 6-
point Likert-type scale) about DNP use and users. The
five statements were formulated based on the typical
views propagated in the Internet forums. This direct
approach offered a context specific focus on DNP
among those who have personal experience with the
substance.
To explore the context in which decisions about tak-
ing the risk with DNP were made, the survey also con-
tained one question assessing the level of concern about
the DNP product before use (recorded on a 10-point
scale ranging from 1 = not concerned at all to 10 = very
concerned); and whether DNP users have past and
current experiences with fat-burners (“Do you currently
take or have taken fat burners?”; recorded as yes/no) and
past experience with illegal supplements (“Do you have
any past experience with illegal supplements?”; recorded
as presence vs. absence without specifying the type of
substance). Normative estimation of DNP use was mea-
sured with a single question where participants were
asked to estimate the proportion of bodybuilders who
use DNP (0 % means nobody and 100 % means every-
body). Along with the demographic details (age, gender,
ethnicity and country of residence), information on
height, current and ideal weight, current and ideal body
fat percentage, weekly training times and type of gym
used was recorded. Participants were also asked from
what source and in what form they obtained DNP; and
how they ensured (if they did) that the DNP is genuine
and pure before they ingested and whether they used
other supplements while using DNP.
Ethics, consent and permissions
The study was approved by the Kingston University Faculty
of Science, Engineering and Computing Research Ethics
Committee. Participation was completely anonymous and
voluntary. Consent to participate was implied by voluntar-
ily completing and submitting the survey. These condi-
tions, including the implied consenting procedure and use
of data, were clearly stated at the start of the survey.
Data analysis
Data from surveys and analytical results were entered
(Study 2) and downloaded (Study 3) into Excel spread-
sheets. Data were cleaned and formatted for statistical
analyses. Results from Study 1 were entered into a word
document. Descriptive statistics (means and standard
deviations) were used to show the data characteristics
for the sample. Group comparisons were performed
using independent samples t-test (t) and analysis of vari-
ances (F) or Wilcoxon test (Z) for nonparametric data.
Relationship between the reported and estimated DNP
user numbers was tested using Spearman r. Associationsbetween categorical variables were assessed with chi-
square test using Fisher’s exact tests for significance.
Statistical significance was set at p < 0.05. Following the
reporting guidelines for statistical tests in medical and
behavioural research [42, 43], respective effect sizes
(d, partial eta squared and w) were reported for all
non-significant statistical tests and means and stand-
ard deviations were provided for all comparisons.
The magnitude of the effect was discussed according
to the reference values recommended by Cohen [42–44].
Effect sizes were discussed in both theoretical and prac-
tical implications. Assuming that the small sample size,
coupled with large standard deviation, result in a loss of
power in cases where the effect size is small to medium,
we also reported detailed information to enable a priori
calculation of the required sample size to reach statis-
tical significance at the conventional 0.05 and the newly
recommended 0.005 levels [45] to inform future research
and facilitate replicability.
Statistical analyses were performed using IBM SPSS
v22. Respective measures of the effects were obtained
from the SPSS output where available or calculated
using the online meta-analysis effect size calculator [46].
Qualitative responses were analysed using applied
thematic analysis [47], following the guidelines set for
thematic analysis in psychology [48]. Applied thematic
analysis was selected as analytical framework for the
qualitative responses because it is an inductive proced-
ure that supports theoretical model development and
finding solutions to real life problems. It is a positivist/
interpretative approach in a sense that assertions must
be supported with evidence (data). Applied thematic
analysis is particularly suited for the data at hand
because it allows quantification and inclusion of text of
any length (i.e., survey questions can be treated as text)
and facilitates studying a particular topic (users’ views
of DNP safety, effectiveness and risks) rather than indi-
vidual experiences.
Results and Discussion
Study 1: Information available on DNP from the internet
The internet search, after removing duplicates, yielded 92
websites of which 36 supplied DNP at the time of writing
this article (August 2015). The search also identified a sig-
nificant number of retailer websites which are no longer
available. Details of the websites are provided in Add-
itional file 2: List of retail web-based sites and discussion
boards/forums. A comprehensive list was not attempted
because of the fast changing nature of the DNP market.
Rather, it is a snapshot of the situation illustrating the
abundant supply and informal unchecked information
available on the Internet. A considerable number of online
retail sites (trading in anabolic steroids and other body-
building supplements) that do not sell DNP still provide
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availability (e.g., from the UnderGround Lab). Forums are
characterised by multiple threads started on various as-
pects of DNP use. These discussion threads typically initi-
ated with an enquiry about DNP availability and use. Basic
information; dosage; supplementation; side effects and al-
lergic reactions; concurrent use of other bodybuilding sub-
stances and experiences are readily shared but responses
tend to be void of or explicitly refuse suggesting retailers.
Information on DNP manufacturers is shared among
users, again, often initiated by someone with intention to
purchase a particular brand. Independent of the legality of
the transaction, word-of-mouth quality assurance and cus-
tomer endorsement appears to be a prominent features in
building trust for online purchases of DNP, which is in
line with the general literature on online buying [49–52].
Detailed diary-like blogs on daily experiences with
DNP are fairly common. Most of these blogs offer de-
tailed accounts of the DNP ‘self-treatment’ regime, along
with users’ expectations, fears and hopes, and experi-
ences. Similarly to the phenomenon observed in the
community of psyhconauts, the educated and informed
recreational drug users [53, 54], lived experiences with
DNP are often translated into advice for others who
wish to experiment with the same substance. Without
exception, these advices about DNP use aim to make the
experience–risks acknowledged–better and safer.
Online availability of DNP
The incongruence between the geolocations of the ip
addresses and shipment information (where available)
indicates that DNP suppliers 1) possibly hide behind
layers of web-pages; making policing difficult and 2) use
multiple websites simultaneously. In some cases, DNP is
sold with health warnings or a statement that the sale is
not for human consumption and “packed in capsules
only for means of safe transportation” (quote from the
Q&A section of an online retail site), but the overall
impression of the retail sites is that DNP is openly sold
as an effective fat-burner/bodybuilding supplement.
Images on retail sites either show the compound as pow-
der, capsules or pills; or the packaged product with manu-
facturer’s labels. Manufacturers, when identified, include
Biomax Lab (Turkey), BR Europe which is now UmForte
(US), BodyAdvance Performance (US), Gen-Shi Pharma-
ceuticals (Japan), AbaXen Pharmaceuticals (US), Aeolis
Pharmaceuticals (US), TrigoPharm (The Netherlands) and
Wildcat/British Research Laboratories (UK). DNP is sold
and labelled ‘as is’ with only one exception found. The pack
from Gen-Shi Laboratories shows L-Glutamin but the
retail site clearly identifies the product as DNP, giving the
compound name, manufacturer, dose, quantity. In addition
to online retail stores, D-Hacks Lab (UK) and Crystal Heat
Labs (UK) supply DNP through Facebook. Concerningmismatch in information on wholesale sites is not uncom-
mon. For example, one retail site depicts DNP as yellow
powder but with “steroid powders or liquid” overlaid on
the image and discusses the recreational use of an entirely
different substance, dextromethorphan (a cough suppres-
sant), beneath the image under Application.
On most online retail sites, purchase requires regis-
tration and setting up a customer account. Many of
them accept major credit cards. Alternative payments
include bank transfer, Western Union, Moneygram or
‘bitcoin’. In terms of getting the DNP orders to cus-
tomers, online retailers pride themselves for high suc-
cess rates going through customs and offer a
replacement guarantee (free replacement once with
proof for the seized package) for most countries but
Australia, Canada, New Zealand, Singapore and South
Korea where only one shipment is made. Under ship-
ping information, retailers explain in detail that they
avoid identifying themselves as pharmaceutical-related
or labs to avoid suspicion, using discreet packaging that
does not identify the content and employ frequent
changes to their packaging not to alert customs (i.e.,
using non-descriptive labels or disguise DNP as some
other product, e.g., turmeric if DNP is shipped in pow-
dered form). When specified, shipment is often made
through Turkey. One typical example is:
“We have a success rate of 98 % at USA, Canada and
European customs with Registered Mail Method only.
Our company eliminates the remaining 2 % risk and
gives you a customs seize guarantee. If your order is
seized at the customs, we ship one more time for free.
Seizured orders must be sent to a different address
because customs may flag your address. And the best
part is you do not have to pay the shipping charge
again. We don’t have any other options of refund. We
cannot resend seized orders to Australia because of
extreme custom security. Orders from Australia are
welcome but no one can give a %100 guarantee no
matter how professional and safe packing is done”.
For obvious reasons, online retailers do not openly dis-
close how it is achieved but as one user said: “trust me,
anyone could open the package and they would not have
a clue”.
Online accounts of experimenting with ‘uncut’ DNP
The informally “recommended” dosage ranges between
200 and 600 mg, often recommending that new users
start at a lower dosage and increase it gradually if tolerated
well. For comparison, 100 mg equates to 1.4 mg/kg for
healthy average male (70 kg); 1.7 mg/kg for healthy aver-
age female (58 kg); 1.2 mg/kg for average bodybuilder
male (81.5 kg); 1.6 mg/kg for average bodybuilder female
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with ideal weight adjusted for bodybuilding [55, 56].
Health warnings are associated with a single dose (i.e., it
should not exceed 300–600 mg at any one time) and dur-
ation of the DNP regime. The latter varies between
recommended cycles (i.e., 8 days on-8 days off; 7–10 day
cycle; 2 weeks on–2 weeks off; 20 or 30-day cycle, with
shorter cycles tending to be recommended with higher
doses) and total duration (i.e., do not exceed 20 days).
According to some accounts, other substances with simi-
lar effects such as Clenbuterol (a bronchodilator with fat
burning properties) are sometimes also taken in combin-
ation with, or in between, ‘on’ periods. Taking antihista-
mines (e.g., Benadryl or other allergy medications,
quercetin extract) to manage allergic reaction is suggested,
along with vitamins and stimulants such as caffeine. Kra-
tom, a plant with stimulating effect at low to moderate
dose [57], which makes monotonous hard physical work
more bearable, is also gaining popularity among DNP user
bodybuilders; and it has been speculated that it could
counterbalance the lethargy caused by DNP. Other sub-
stances discussed for use alongside DNP include appetite
suppressants, thyroxine (T3) and insulin-with mixed views
and explanations.
Most concerning is that in the absence of easily access-
ible information and a universal safe zone for dose and
exposure duration, this individual, personal-experience
based advice for length and pattern for the ‘treatment’
regime is highly concerning for the public. None of these
information sources draw people’s attention to the fact
that DNP’s harmful effects are highly dependent on the
individual’s tolerance. The only recommendation is to
start at a lower (200 mg per day) dose and increase if tol-
erated well. Based on the available scientific evidence, even
this lower dose can be harmful for some [26].
Critically important from the public health point of
view are the patterns of use by bodybuilders and
extreme dieters-as recorded on Internet blogs and for-
ums - which provide an overwhelming body of evidence
that dedicated users take the ‘uncut’ compound (in tablet
or crystal form). Thus, the issue is not only that DNP
might be sold in disguise; nor is the contamination with
DNP and the trace amounts that regulatory bodies need
to be worried about, but the easy access to the pure
compound. The potential consequence of this is that
pure DNP may not only be purchased and consumed by
the dedicated and highly experienced bodybuilders who
are well-prepared, but it is just as readily available to
the naive users who lack experience in taking risky
substances.
Several postings were concerned with the legality of
obtaining DNP. These discussion threads tend to be
initiated by someone interested in using DNP as part of
their information gathering. Responses to such inquiriesdepend on the country where the responding expert user
resides. Users are cautious about new brands and seek
reassurance for the quality and effectives from other
users.
Most notably, a plethora of postings exhibit remark-
able in-depth knowledge of biochemistry which mani-
fests in postings explaining the mechanism of DNP to
novice users as well as in postings discussing synergistic
effects between DNP and other substances. Reference to
scientific literature is not uncommon but these postings
tend to come from the same members who are most
likely with relevant educational background. Experienced
forum participants make efforts to provide detailed and
informative answers, and take pride in their responsible
and considerate approach. Disapproval of DNP use is
not uncommon suggesting that although DNP use is
prevalent among bodybuilders and avid exercisers, it is
not a universally accepted and approved practice. In fact,
those contemplating DNP use and seeking information
on how to use DNP are often vetted for dietary habits,
exercise regime and previous experience in controlled
weight-loss and maintenance before advice on DNP is
offered. In this tightly-knit, self-regulating community,
novices who take this substantial, knowledge- and
experience-based but impartial advice lightly or discard
the warnings are often scolded for their cavalier attitude
and brassiness. Questions that show absolute lack of in-
vestment into acquiring knowledge (e.g., “is DNP safe?”)
or effort in weight management through diet and exer-
cise are not well received and rebutted with a quick
judgement that the person is “not ready” for DNP.
Discussion forum members sharing their experiences
with DNP appear to be well-informed about the different
forms such as tablets, crystal (sodium dinitrophenolate);
or industrial grade powder; and their strength. These
users are confident and appear to be highly experienced
in using a cocktail of performance enhancing substances
and are accustomed to dealing with (temporary but
often harsh) adverse effects. Although accounts of death
in this experienced community appear in the Internet
postings, the fact that the majority of users survived and
are often satisfied with the outcome of their DNP regime
gives the impression to the public that DNP may not be
as dangerous as the scientific literature and official
standpoints indicate. However, the fact that these experi-
enced users have managed to use DNP “safely” (that is,
using DNP without death or apparent indication for
long-term health consequences) does not necessarily
translate to “safe use” for others, particularly among
drug-naive users or those with minimum experience. On
the contrary, it creates an illusory sense of safety which -
coupled with a potential lack of knowledge about the
strengths of different forms and the complete lack of
regulatory control over these substances and labels -
Fig. 3 Proportion of samples contaminated with DNP obtained from
high street and online retailers
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more, owing to the lack of established level of toxicity, a
dose well-tolerated by one user is not applicable to
another.
Owing to DNP use being a rather clandestine activity
(i.e., difficult to find DNP users in ‘real life’ settings),
researchers use discussion boards to recruit study partic-
ipants, the present study included. Another recent
example appeared briefly in March 2015 on one discus-
sion forum, comprised of a brief “survey” aiming to
explore body temperature related personal experiences
in support for research investigating the potential thera-
peutic effect of DNP in treating hypothermia. The sur-
vey lasted less than 5 hours before the discussion thread
was locked by the moderator and thus only generated a
limited number of, but intriguing, responses. Forum mem-
bers’ responses exhibited a great degree of suspicion, as
well as support for research and remarkable knowledge
about DNP. The extreme difficulty of finding people who
have tried DNP - particularly in real life settings - and
willing to admit DNP use was openly acknowledged.
Study 2: Screening results for DNP in bodybuilding
supplements
A total of 98 samples were collected as follows: 77 were
purchased in high street stores across the South of Eng-
land, 16 were purchased online and five samples were
donated through a local gym (of which two originally
obtained from Internet, two from high street retailers
and one from a gym). All five participants who donated
a sample through the gym identified sustained weight
management as the goal, with both being part of a fit-
ness regime and as a quick start to the desired weight
loss also appearing in two of the seven cases. Informa-
tion sources were wide-ranging but notably only one
person mentioned healthcare professionals (among
other sources). The analysis found two of the six sam-
ples positive for DNP. Both were reported as purchased
from UK Internet sites. Although side effects were re-
ported (shaky feeling, anxiety and heart racing), these were
not for the samples that were found with DNP. All partici-
pants expressed a high level of concern about DNP.
Of all samples, 14 were found positive for trace amounts
(<100 mcg/kg) of DNP (Fig. 3). In contrast to high street re-
tailers, a concerning proportion of the Internet samples
were contaminated with DNP. Because DNP was detected
using semi-quantitative methods (for details, see Additional
file 1: DNP method development for semi-quantitative
screening), the results did not afford comparisons of the
concentration between different retail options; nor was it
practically meaningful owing to all DNP levels being
detected as trace amounts. Further interpretation of the
results would warrant a study using a larger sample size
and a fully validated quantitative method.Positive cases were reported to the Food Standards
Agency through official channels. The low concentration
of DNP suggests contamination owing to poor quality
control rather than deliberate adulteration (‘spiking’) to
increase effectiveness. However, the fact that DNP
contamination in these supplements could occur in the
first place suggests that the actors of this market chain
(i.e., manufacturers or distributors) of the contaminated
supplement were also in contact with DNP.
Study 3: Personal experiences with DNP among users
The majority of the participants reported that they exer-
cise three times (n = 16) or more (n = 15) a week. The
remaining minority (n = 4) do not exercise or exercise
only once per week. Seventeen participants use commer-
cial gyms that are part of a chain, nine visits bodybuild-
ing focused gyms and seven identified the gym they use
as sport focused (2 responses were missing). DNP users’
profiles are summarised in Table 1. Seven of the partici-
pants (one female and six males) reported a desire to
gain weight; two males with current use of fat burners.
As expected, no participants in this sample wanted to
increase body fat percentage. It is notable that despite
the considerable variations in the current body fat per-
centage, males in all three age groups aim for an average
body fat around 9-10 % (range = 6–15 %). Means and
standard deviations for each group are displayed in
Table 1. Themes emerging from the accounts of DNP
users’ experiences are quantified in Table 2. Different
sample sizes are due to missing responses.
Reasons
Reasons by which participants retrospectively justified
using DNP were dominantly related to a desire for an ef-
fective weight-loss strategy - either as an end-goal or as
means to an end-goal, as exemplified by reasons identified
as: “Just looking to drop some fat quickly”, “to be able to ac-
complish my goal in 2–3 weeks” and “the opportunity cost
Table 1 Participants body mass index (BMI) and body fat profiles by age groupsa
Male Female
18–25 years 28–36 years 39–45 years 18–25 years
N 22 9 2 2
Body Mass Index (BMI) Mean 27.75 ± 3.70 30.82 ± 3.82 30.85b 21.14 ± 3.11
Range 21.5–35.6 26.2–35.2 - 18.9–23.3
Actual body fat (%) Mean 15.89 ± 4.05 21.83 ± 14.23 14.50 ± 2.12 26.50 ± 2.12
Range 7–25 12–50 13 and 16 25 and 28
Desired body fat (%) Mean 9.84 ± 2.06 9.69 ± 2.06 9.00 ± 1.41 19.00 ± 1.41
Range 7–15 6–12 8 and10 18 and 20
aAge groups were created using k-means clustering maximising distance (F(2,30) = 122.506, p <0.001; all pairwise differences are p <0.001). Differences in BMI and
body fat percentages are not statistically significant
bmissing value
Table 2 Summary of users’ qualitative responses for reasons,
expectations, experiences and steps taken to ensure quality of
the product, presented in decreasing order of frequency
Categoriesa Content Frequency
Reasons Effective/fast fat loss as the ultimate goal 20
Effective/fast fat loss to enable working









Expectations Positive outcome 13
Specific side effects 6
Mixed positive outcome and generic
unpleasant experience
5
Mixed positive outcome and specific
unpleasant experience, including death
3













Negative experience with side-effects 3
Notes:
acategories emerged from the data
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time by 2/3”. Curiosity (“to verify the hype”) and image
enhancement (“recomp[osition]” and “improve image, and
tone up”) were also mentioned more than once.
A smaller, but not insignificant group, rationalised
DNP use as a feasible option after trying for other ways
to manage weights. One participant said:
“I have lost over 60lbs in the past 24 months, yet still
have some very stubborn fatty areas. No matter the
level of cardio or calorie intake I cannot shift this fat.
… DNP can literally and effectively burn fat from your
body in a limited time period. As you can imagine this
appealed to me.” (23 year old male)
Another participant reasoned:
“At 45 when I eat less my metabolism slows to
compensate. I have to starve myself now to lose fat.
Fasting and low carb dieting together resulted in a lot
of muscle loss with any fat loss. My body seems
programmed to preserve fat! DNP allows me to lose
weight on a mild diet that my body would otherwise
just adapt to by reducing metabolism and increasing
catabolism. I am able to keep my metabolism at 100
% or above while eating less resulting in muscle
sparing fat loss. This has been of great benefit to my
overall long term health, despite the mild side effects
during my DNP cycle.” (45 year old male)
Both of these users experienced that diet and exer-
cise alone did not yield the desired fat loss and thus
perceived a need for chemical help. Despite that
DNP is often classed with other diet pills as shortcut
that replaces hard work, exercise and diet [58, 59],
only one participant justified DNP use as a shortcut:
“to lose weight the easy way, can be very lazy
sometimes”.
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nalised DNP use as a countermeasure for the calorie in-
take. She said that using DNP would allow increased
calorie intake without consequences on weight: “wanted
to slightly increase the amount of calories I consumed
while still losing weight”. Such use of DNP is akin to the
use of diet pills by those with eating disorders as a com-
pensatory behaviour [60–62]; and also noted as a con-
tributor to Eloise Parry’s DNP-overdose [63].
DNP use patterns and experiences
The quantitative results showed that the majority of
DNP users (n = 25) have had previous experience with
illegal supplements other than DNP. Thirty-one DNP
users reported concomitant supplement use. The type
of gym they visit and past experience with illegal supple-
ments (χ2(2) = 1.188, p = 0.595, w = 0.182) or concomi-
tant supplement use were unrelated (χ2(2) = 1.196, p =
0.405, w = 0.307). Half of the sample (n = 18) reported
current use of fat burners with type of gym being unre-
lated (χ2(2) = 2.868; p = 2.77, w = 0.311).
For most respondents, DNP fulfilled the expectations
without notable side effects. Such positive experience is
exemplified by the following quotes: “lost approx 1 lb of
fat per day”, “I cut 35lbs of fat within a month” and “rate
of fat loss and sweating were exactly as reported, even bet-
ter didn’t die luckily”. Others had mixed feelings about
DNP. One 23-year-old male exerciser who used DNP for
image improvement said the DNP “did the job but [with]
horrible side effect like headaches”. Another user noted but
immediately mitigated an unwelcome effect on diet: “crav-
ings were unbearable so diet suffered but didn’t gain any
fat” (28 year old male). Many others reported a degree of
reality adjustment between expectations and experiences:
“Had plenty of weight loss- wasn’t as easy as I had hoped”
and “the weight loss is easier, but not as easy as some
claim”, or even “less weight loss than expected”. The self-
reported symptoms were irregular heartbeat, nausea,
vomiting, agitation and insomnia, which are in line with
those reported in the literature [12, 13].
A few participants said that the side effects were less
taxing than what they were prepared for: “side effects
seem largely overstated” and “I did not get as hot or
sweaty as I expected, but this may be because it is
winter and relatively cool everywhere”. One
participant explained:
“… for me 125 mg/day was enough to lose 1 lb of
fat/day. Most of the day I didn’t notice the side effects.
At night or in a hot room it was uncomfortable due to
the sweating and heat but normally I would not notice
the side effects” (33 year old male)Accounts downplaying the side effects - if made on
open Internet forums - may inadvertently underplay the
harshness and potential danger of the drug. In reality,
toxic effects vary widely between individuals and thus
positive cases cannot provide reassurance, or guarantee,
for others having an easy DNP course. Among users it
was notable that despite the negative experiences with
side-effects (e.g., “[DNP] caused allergic reaction” and
“DNP made it hard to catch my breath or more specific-
ally it was harder to expel CO2”), all but two male DNP
users would consider using the substance again. Both
participants who said that they would not use DNP
again were identified curiosity (“see if it works”) as the
main reason for using DNP in a first place and perhaps
saw DNP as one alternative to the desired weight-loss.
Even if both said they wanted to lose weight and they
were satisfied or to some degree satisfied with the re-
sults, they expressed no intention to use DNP again. In
the small subsample of those who highlighted negative
side effects without being specifically prompted (n = 5),
there was no clearly observable pattern between the
forms or sources of DNP but apparently affected their
satisfaction with the drug (all reported that they were
somewhat satisfied with the results). Notably, 48.6 % of
the sample (n = 17) felt that their expectations about
DNP were fulfilled with the remaining 51.4 % (n = 18)
reporting fulfilment to some degree. This relatively posi-
tive view, along with qualitative evidence suggest that
users were knowledgeable about the drug and its desir-
able and undesirable effects and were prepared for deal-
ing with the unpleasant side effects. As one participant
summarised:
“I had fully researched DNP side effects, including
death. I expected extreme heat and sweating,
lethargy, headaches, staining of bodily fluids
and skin (yellow). I expected to lose 1 lb per
day.” (23 year old male)
Negative experiences were equally related to effectiveness
as a weight loss agent and harsh side effects.
Access to DNP
The anonymous Internet purchase was the dominant
method of obtaining this unlicensed drug (n = 26), of
which only one was through the “dark web”, SR2. In
only 6 cases users reported that the DNP was obtained
from a fellow bodybuilder and only one each identified
‘dealers’ and ‘shop’ as the source for obtaining DNP.
Almost all of those who identified the Internet as a source
for DNP checked out the reviews about the retailer before
(e.g., “used a very trusted internet source”) or made purchase
based on recommendation (e.g., “[DNP] was from well
recommended source”).
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ensuring trust in the quality and relative safety of the
substance, expresses as the “great reputation of the guy”
or “reputation: reviews from others on internet forums”.
DNP users’ responses suggest that they tend to rely on
customer reviews (e.g., “I ensured that I got it from a
reputable source with lots of good reviews”) and word-of-
mouth (e.g., “[DNP] was from well recommended
source”) when purchasing from a website. When buying
from a seller, as opposed to an impersonal online retail site,
personal past experience (e.g., “I trusted the supplier” and
“trusted source on other matters”) was the most often cited
way of ensuring that the product was genuine. Among the
responses DNP users offered, there was some indication
that suppliers of DNP are also users, which has helped to
build reputation and ensure trust in them and in their
products (e.g., “I had the same symptoms as a previous
dealer I went through”).
Despite the regulation that DNP cannot be sold for
human consumption, in most cases, DNP was in
capsules (n = 26), with some purchased in tablet form
(n = 3). This is consistent with the results from the
Internet search which showed the DNP sold in online
shops is typically in 100 mg or 200 mg capsules. Only
in 6 cases DNP was purchased in powder form, which
is how DNP is typically used for industrial applications.
No association was found between the form and source
(χ2(8) = 13.176, p = 0.094, w = 0.615).
Concerns and risk management
All 35 users in our sample knew the health risks associ-
ated with DNP intake and made an informed choice.
Characteristically for the sample, DNP users were not
only aware of, but were also prepared for or even took
pro-active steps to manage the expected side effects.
Participants typically said that “I was on top of water
and electrolytes” and “[I expected to] feel ill, heat, dehy-
dration. I planned ahead for all foreseeable side effects.”
The level of concern about the quality of the DNP var-
ied widely among the DNP users. The concern about
DNP in this context refers to whether the substance pur-
chased ‘underground’ was of high quality, unadulterated
and pure. Some participants tested or get the substance
tested before use. One respondent, who later stated that
he did not use DNP after all, said: “I ran it through an
HPLC and compared to Sigma-Aldrich 99.9 % DNP”,
whereas others sent the DNP off for laboratory testing: “I
used WEDINOS substance testing service (Welsh health
board run service) which confirmed DNP” and “third party
testing”. (Note: to date, WEDINOS [http://www.wedinos.
org] has recorded 4 samples with DNP as major ingredient
in powder, pill, crystal and capsule format with one each, all
submitted in 2014).Half of the sample, however, relied on reputation of the
seller/retail (“ensured that I got it from a reputable source
with lots of good reviews”). Others physically examined the
DNP capsules or pills: “Looked for the characteristic side
effects and opened a cap, saw yellow crystals”. Using one’s
own body to test was not uncommon. A quarter of the par-
ticipants reported some form of self-experimentation for
testing DNP (e.g., “after taking a few doses the side effects
matched up exactly, and there isn’t much else that gives
those specific sides” and “[I relied on] reputation, plus I had
the same symptoms as a previous dealer I went through.”).
As one DNP user explained: “I opened that capsules and
looked at the crystals. I took the pills and started feeling the
side effects. There was nothing else I could do to ensure the
quality, but it was bought from the most reputable seller at
the time.” Only four users said that they took no action at
all to ensure that DNP was genuine.
Attitudes
Attitudes toward DNP use and users were quantitatively
measured with five statements (Fig. 4). Cumulatively, the
attitudes which users hold about DNP suggest that DNP
use is considered a sign of being committed and risks
with DNP are seen as ineffective “scare tactics”. The
strongest agreement (4.77 ± 1.46 on a 6-point scale
where scores 4, 5 and 6 indicate a degree of agreement)
was recorded for getting help with advice and medical
supervision instead of scare tactics.
Qualitative responses provided overwhelming support
for the explicitly expressed demand for accurate and
impartial information on DNP. As one participant (31
year old male) said: “there really isn’t much out there for
DNP aside from 1930s studies, anecdotal stories, and
‘bro science’”, identifying the Internet forums as main
information source.
“There’s a lot of information on DNP on forums,
however if there were more information about how to
use DNP would be much better on respectable sites.
All academic paper speak badly about DNP and how
it’s a pesticide but it has more uses as a fat burner.”
(22 year old male)
Notably, in those who ask for more information, the
danger of DNP is clearly acknowledged and not the
drug but users are blamed for detrimental health
consequences:
“DNP is not right for everybody, but it was and is the best
diet aid I’ve ever used. Proper understanding of the effects
of DNP is necessary for the proper application of it. Any
tool can be a weapon of self-destruction in the hands of a
fool. Don’t outlaw tools just because fools will misuse
them. DNP is already hard enough to get for those who
Fig. 4 Users’ attitudes toward DNP and prototype perceptions of DNP users
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to surgical intervention for those who have difficulty
losing weight or have devastating metabolic syndromes
that modern medicine fails to allow DNP to be used to
treat. A quick drop of 50 pounds would do your average
diabetic person a world of good! DNP is a relatively
effective non-invasive tool to do that. Don’t throw the
baby out with the bath water! Far more people have died
from obesity and metabolic related syndromes or had
decreased quality and length of life than will ever be lost
to DNP abuse. DNP has the power to do so much good in
the hands of caring health practitioners and educated
citizens.” (45 year old male)
Another participant explained:
“DNP with the right education and supplementation is
fine! However, people are stupid. If you can die from
something, people WILL die from something. DNP is no
exception. However to the educated people who research,
DNP is an effective supplement.” (31 year old male)
Media reports on DNP-related death cases appear to
support this argument showing that many DNP deaths
were caused by reckless use or incidental overdose;
either by young individuals who suffer from some form
of eating disorder or inexperienced users [63–66]. One
of the most recent examples is the tragic death of Eloise
Parry who apparently took eight diet pills containing DNP
[63]. Following this incident, in connection with its Oper-
ation Pangea [http://www.interpol.int/Crime-areas/Pharma-
ceutical-crime/Operations/Operation-Pangea] - investigation
targeting online sales of pharmaceutical substances - and
in collaboration with the World Anti-Doping Agency,
the Interpol issued an Orange Notice warning about
DNP as a potentially lethal diet aid [http://www.interpol.int/
News-and-media/News/2015/N2015-050]. However, users’
views on DNP show a stark difference to the official stand.
As one 22 year old male said:“DNP, in itself is a fantastic drug… There is nothing
that can even come close to the results. Now granted it
is a dangerous drug. It’s extremely easy to OD
[overdose] on the shit and there’s no reversal. That
typically scares people, which is why the FDA banned
it. Human analogy suggests that if something works,
take more. That isn’t the case with DNP.”
DNP was considered as a very potent and useful drug
by many users in this sample: “DNP is highly effective
and low doses work the best while avoiding highly-
oxidative and side-effect inducing problems.” (23 year old
male). The danger in overdosing and from the side ef-
fects was readily acknowledged but also counter-argued
that “Any drug is dangerous if misused, info on the right
dosage would be beneficial”.
Reference to alcohol and tobacco - the two substances
typically used as baselines for any supportive argument
for relaxed drug regulation - also appeared in the sup-
portive argument for DNP:
“I believe this chemical is dangerous but with proper
precaution the side effect and danger is worth the risk.
I do not consider it any more dangerous than alcohol
or cigarettes. I believe medical authorities should
research this as a partial cure for obesity. Under the
supervision of a medical professional I believe this
could improve the quality of life of millions.” (33 year
old male)
Some participants exhibited a nonchalant attitude to-
ward one’s own body, health and wellbeing. More than
one participant risked health consequences from DNP
simply for satisfying curiosity (e.g., “want to see what it
did, I was on it for a week only” and “to see if it actually
worked that good”).
One participant, who paradoxically expressed very
high level of concern about DNP but had previous
experience with illegal supplements, said: “[I expected]
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falling over and dying but meh…”. Another participant,
who expressed no concern about DNP stated on the
question how it was ensured that the DNP purchased
was genuine: “test[ed] it in my body and see what hap-
pens”. Others were more cautious and thoroughly
researched DNP before they decided to try it. For
example, a 22 year old male said: “To be honest I was
rather scared, once I did a little 10 day cycle I was com-
fortable with it. I’m on my third cycle right now. Started
at 261lbs. Take all the supplements and don’t be an over-
zealous fat retard and you’ll do fine on DNP.” Another
participant, 45 years old male, said: “I did a lot of
research, exercised a lot of caution, and have had a life
benefitting experience with DNP. My research led me to
see that most who died from DNP had either eating dis-
orders or a lack of self control/and poor judgement.
Death is hardly the norm.” In both responses, the pre-
vailing belief among DNP users manifests, namely that
those who were in serious trouble with or died because of
DNP either made a mistake (considered as an avoidable
factor) or suffered from an eating disorder (considered as
a non-relevant feature).
Normative perceptions
On average, DNP users estimated that a quarter of body-
builders (23.05 ± 20.00 %) use DNP. Detailed normative
perceptions by user details (current use of fat-burner
and having experience with other illegal supplements)
are depicted in Fig. 5. The difference between current
fat-burner users and non-users was small and non-
significant (t(16) = 0.059, p = 0.954, d = 0.029, 24.55 ±
21.96 % vs. 25.14 ± 19.25 % for current users (n = 11)
and non-users (n = 7) respectively). The small effect size
suggests that current behaviour with similar drugs does
not influence the estimation regarding DNP. Equally,
there was an observed but statistically not significantFig. 5 Comparison of the perceived normative estimation of DNP use amo
substance is used at the time of data collection and (b) having experiencedifference in estimations (t(18) = 0.730, p = 0.478, d =
0.379) made by those who only used DNP (n = 6; mean
estimation = 18.00 ± 15.94 %) from the array of ‘illegal
supplements’ versus those with more experience (n = 14;
mean estimation = 25.20 ± 21.68 %). From literature
precedence, it was expected that the perceived legality of
the drug - possibly through mental representation of
DNP - could influence the estimation of DNP use
among others. In similar context, it has been observed
that athletes involved in socially detested behaviour
(e.g., doping) tend to overestimate the same behaviour
among others compared to those who are absent, but
with no difference in estimations of the use of perform-
ance enhancing aids such as nutritional supplements
that can be used without restrictions [67–69]. In the
present sample, the observed difference (18 % vs. 25 %)
lacks statistical support for the legality effect on pro-
jected use; and thus may only reflect random variation
in the sample. Future research specifically tailored to
investigate projection bias is needed to ascertain if the
difference manifests in subsequent studies with robust
evidence for statistical significance.
DNP represents a grey area on multiple accounts.
Technically, DNP is not an illegal drug to take, but it is
not licensed for human consumption, thus selling for
such purpose is illegal. From the cognitive point of view,
it is an interesting case because DNP may very well be
perceived as illegal owing to the clandestine nature of
purchase and use, even if from the legislative point of
view, there is nothing illegal about buying and using
DNP. A similar phenomenon has been observed regard-
ing performance enhancing nutritional supplements
among athletes [70]. Thus we expected that those using
other illegal substances may automatically class DNP as
illegal whereas those who do not use anything illegal had
a more accurate view. Perhaps it is because legality is
important to these users, not wanting to cross theng bodybuilders and avid exercisers based on (a) whether fat-burner
with other illegal supplements
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experience with illegal supplements already did so. Fur-
ther research with experimental design manipulating the
legality condition is needed to ascertain whether a heur-
istic bias regarding DNP exists (i.e., DNP users who also
use other illegal bodybuilding substances may subcon-
sciously include DNP in that category whereas those
who stay away from illegal bodybuilding substances may
not see DNP as illegal). The importance of this aspect
lies in the potential effect on prevention strategies and
communication.
Contrast between the Internet and real life
Break-down of the estimations by the type of gym
(Fig. 6a) shows an interesting - and intuitively unex-
pected -pattern. DNP users attending leisure/exercise-fo-
cused ‘chain’ gyms give much higher estimation for DNP
use among others (28.45 ± 23.09, n = 11) than those at-
tending sport- or bodybuilding focused gyms (13.75 ±
17.50; n = 4 and 15.75 ± 11.79; n = 4), respectively).
Although the difference in projected estimations did not
reach statistical significance, the effect size suggests that
the lack of statistical significance is the function of the
interplay between the small sample and large variance
(F(2,19) = 1.053; p = 0.372; η2 = 0.116), resulting in the
test being underpowered to reject the null hypothesis
when the difference between the three groups may exist.
Further research with adequately powered statistical test
is warranted.
On the contrary, the visibility of DNP use through the
reported known proportion of DNP users (Fig. 6b) shows
the opposite pattern, with the highest proportion reported
by people attending bodybuilding focused gyms (0.262 ±
0.375 vs. 0.215 ± 0.440 vs. 0.162 ± 0.320, respectively for
bodybuilding (n = 6), sport (n = 5) and leisure/exercise-
focused (n = 10) gyms). The difference was not statistically
significant and the effect size was small (F(2,18) = 0.144,Fig. 6 Comparison of (a) the perceived normative estimation of DNP use a
the type of gym used in the samplep = 0.867, η2 = 0.016). The reported proportion of
known DNP users was surprisingly low across the sample.
Against the average number of bodybuilders personally
known by the sample (11.38 ± 14.50), and the estimated
normative prevalence at 23 %, the known number of DNP
users among them (1.12 ± 2.05) barely reaches 10 %. The
average number of DNP users expected from the pro-
jected prevalence (2.63 ± 4.07) significantly exceeded the
average number (1.24 ± 2.46) of reported known users
(Wilcoxon Z = −2.274, two-tailed exact p = 0.021, point
probability p = 0.002), with a significant positive correl-
ation between the reported and estimated DNP user num-
bers (Spearman r(18) = 0.665, p = 0.003).
Taken together, these results suggest that DNP practices
and experiences are shared online, but not in real life.
DNP use appears to take place in isolation. This may
partly so because of the social disapproval of DNP use,
even among bodybuilders; but also because managing the
side effects (profuse sweating, skin discoloration, etc.) in
public is difficult. In fact, new users are advised in discus-
sion forums to start the cycle when on holiday if they are
in employment. Conceivably, sharing experiences online is
a way to deal with isolation and loneliness during a DNP
course. If this is the case, online forums play an important
role beyond being a compendium of DNP knowledge; and
it warrants further investigation.
During data collection we encountered numerous
cases where people, who willingly shared their experi-
ences with DNP and readily offered information and
advice to other forum users, were initially suspicious of
a newcomer asking questions about DNP and were not
very willing to participate until the investigator gained
trust and became accepted in this unique group. Perhaps
DNP in a sporting context, owing to its high risk and
harsh side effects, is similar to harsh drugs among sub-
stance users, where people are much more ready to admit
using a relatively harmless substance (e.g., smokingmong bodybuilders and avid exercisers and (b) visibility of DNP use by
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drug” use (e.g., snorting cocaine or injecting heroin).
Whilst the stigma attached to psychoactive drugs has two
facets (addiction and criminalisation), for DNP, it is con-
ceivable that such distinction is mainly driven by the
degree of health risk and rather than legal consequences.
The high estimating of use by leisure/exercise gym
users (which is likely to be an over-estimation at 28 %) is
concerning on two counts. First, against the relatively
low reported number of deaths from DNP, it can create
a false sense of security by believing that DNP use is a
common and safe practice. Secondly, this group is likely
to be the most naive and least experienced when it
comes to using “hard” sport drugs (e.g., anabolic ste-
roids, hormones, other fat-burners such as Clenbuterol),
dosing properly and managing adverse side effects. As
one ex-professional powerlifter (a 22 year old male)
offered for explanation: “Some bodybuilders may use
other drugs to the same effect- clen [clenbuterol] is espe-
cially popular, that is why my estimate for DNP use is so
low”. Another participant, a 23 year old male, linked
DNP use to anabolic steroids: “Typically DNP users are
mostly bodybuilders that are already on anabolics. I was
not on anabolics and I have never taken them so my re-
sults may not have been as good as others on online for-
ums.”. Because we did not ask the participants to reveal
full details of their supplement and substance use, future
research is required to ascertain the relationship be-
tween DNP and other, legal and illegal, substances.
General discussion and policy recommendations
It is reassuring that pure DNP (or as active ingredient at
the typical dose of 200 mg) was not found among the sup-
plement samples. However against this background, a po-
tentially dangerous discrepancy emerged between the
views of users and regulators about how DNP is marketed
and sold. Whilst DNP is marketed as an effective weight-
loss aid, DNP as active ingredient is disguised for shipping
purposes only (i.e., labelled as turmeric; or shipped in
unlabelled ‘discreet packaging’ to avoid detection and con-
fiscation by customs or the police) but it is clear to the
users what they ingest. Owing to the grey area in legisla-
tion, there is no need for sellers to disguise DNP under
fictitious supplement names to evade FSA or equivalent
regulatory bodies worldwide. DNP can be, and is sold ‘as
is’ over the Internet, as long as it is labelled as an indus-
trial- or research chemical. On one hand, it is comforting
because it lessens the chance for inadvertent exposure.
Paradoxical as it might be, it is also in the sellers’ best
interest to supply DNP with a formal warning that it is
not intended for human consumption because it shifts the
responsibility from the seller to the user. The user who
knowingly ingests DNP despite the legal and health warn-
ings, for all intents and purposes, makes an informedchoice and willingly and voluntarily put his/her own
health at risk. If DNP is - hypothetically - sold in disguise
as a fat-burned supplement without specific reference to
DNP being the active ingredient, if something goes wrong,
the manufacturer/seller can be charged with manslaugh-
ter. On the other hand, with positive feedback and sup-
portive attitude toward DNP use as an effective fat-burner
brimming the Internet, coupled with the easy availability
of DNP, there is a danger that naive dieters or members of
vulnerable groups who are unable to make rational and in-
formed decisions about weight-management practices, are
tempted to try DNP. Because the potential DNP user
groups are qualitatively different, a one fits all approach to
prevention is not likely to be sufficient. The naive and vul-
nerable need protection with strong preventive measures,
whereas the community of determined and committed
DNP users would benefit from information, medical help
and harm-reduction. Regulators and policy makers are ad-
vised to proceed with care in this tightrope-balance situ-
ation. Tightened access control is likely to protect the
general public but will not dissuade determined users
from DNP. As it has been observed with other illegal-
and performance-enhancing substances [71, 72], if sell-
ing the substance poses too high of a risk to distribu-
tors, social dealers who are socioculturally similar to
buyers move out and are replaced by organised crime.
It has been established that increase in punishment for
the lesser crime inevitably drives criminal activities to-
ward the more serious end of the spectrum if the more
serious crime also means a reduced chance of being
caught [73].
Because of the importance of trust, reputation and
personal relationship, it is further assumed that the ano-
nymity of the ‘dark net’ does suit the bodybuilding drug
market. Based on one dominant outcome of this study,
namely how DNP users ensure quality and safety, it is
reasonable to assume that relationship between buyers
and suppliers in the bodybuilding drug market resembles
a form of social dealership; albeit in most cases, the rela-
tionship maybe virtual and transactions are made
through the means of the Internet. Thus, trust in sup-
pliers may have different dimensions which are possibly
negotiated through additional roles (e.g., also supplying
advice about what substance and how to use, including
harm-reduction measures or selling other, more com-
monly used performance enhancers). If this hypothesis
gains empirical support in the future, then suppliers in-
deed play an important role in keeping the bodybuilding
drug market relatively safe. If harsher penalties drive the
knowledgeable, and somewhat customer-oriented suppliers
out of the market because selling such substances is no
longer worth the risk, then they will inevitably be replaced
by the profit-oriented suppliers without knowledge specific
to the drugs (e.g., anabolic steroids, fat-burners, pre-
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ents. Then DNP may move out from the highly visible
Internet to the invisible dark net, making it less traceable
or controllable. It may also motivate manufacturers to mar-
ket DNP in disguise.
Contamination or adulteration with DNP was found in
14.3 % of the tested bodybuilding supplements in low
concentration. Almost half (44.4 %) of all Internet-
sourced samples were contaminated compared to only
7.7 % of those obtained from high street retailers, which
suggests that controlling effort is best concentrated on
supplements available - or in some cases, only available -
from online retailers. The low representation of gym
sample prevents making meaningful conclusion but
future investigations should specifically focus on samples
bought in gyms because the original source of these sup-
plements could be the generally cheaper online retail
network and/or underground labs. The concentration of
DNP in these supplements was well below the levels of
use which bodybuilders report, and far from the signifi-
cant exposure of 30 mg/kg dose used in an in vivo rat
study to induce sufficient increase in energy demand for
fat loss [74]. Thus, deliberate adulteration and violation
of the labelling requirement [38] is less likely than con-
tamination owing to poor quality control.
Despite warnings issued by food standard agencies and
national health services, online retail sites that are
actively promoting and selling DNP are easily found on
the Internet. In online retail sites, information on health
risks and side effects associated with DNP use are not
always listed but when they are, their seriousness is
downplayed and advice is offered for avoiding side
effects and “safe” use. People who are interested in try-
ing DNP can find a plethora of accounts of first hand
experiences and user advice on how to avoid side effects
including dosage, duration, incremental increase in
amount taken to build tolerance, recommended daily
water intake and diet plans to follow while taking DNP
from discussion forums and blogs.
The survey results, coupled with the Internet forums,
provided immutable evidence that DNP is knowingly
used whilst the risks associated with such use is ac-
knowledged. Motivated by the desirable goal (fat loss,
either as an end result or a mean to an end), dedicated
bodybuilders and exercisers have used and, by large, plan
to continue using DNP. This group appears to be quali-
tatively different from those described in the media for
DNP death- or near-death incidents. DNP users in our
sample specifically sought DNP with the intention to use
or try; as opposed to using a slimming aid that happens
to be or contains high dose of DNP.
Based on the quantitative results and qualitative
accounts, DNP users’ profiles contradict the commonly
held views of “mindless risk-takers” and appear to bevery similar to the profiles observed for non-medical
steroid users [75]. Their approach to DNP focuses on
being experienced in controlling weight and in con-
trolled weight-loss practices, and they warn new users
against thinking of DNP as a quick fix. In fact, DNP
users exhibited a high degree of control and knowledge
as well as exercised precautions. Experienced DNP users
act as gatekeepers for sensible and safe use, which indi-
cates the presence of a grass-root, self-organised and sus-
tained harm-reduction. This observation is underscored
by the overwhelmingly strong theme that emerged from
the qualitative responses, expressing the desire for accur-
ate knowledge about DNP and help in using DNP safely.
Notably the language used in qualitative responses is re-
markably similar to those shown in studies investigating
bodybuilders’ views about anabolic steroids and other per-
formance enhancing substances [76–81]. However, inter-
preting these as evidence for moral disengagement [82]
may inadvertently pose a moral/ethical frame to a
behaviour which – at least at the time of this study in this
population - does not break legal or social rules. It is with-
out doubt that DNP use is a controversial behaviour, even
among bodybuilders, and highly risky in terms of potential
health consequences. Applying the moral disengagement
process of cognitive restructuring of inhumane conduct
against others into a worthy or acceptable behaviour inev-
itably labels DNP use as ‘inhumane’ or ‘immoral’. Apart
from the crucial difference that DNP directly affects no
one but the user (i.e., there is no victim), this is the pre-
cise labelling which DNP users argue against. Instead,
in the current legislative context, downplaying these
health consequences and making advantageous com-
parisons, coupled with expressing high confidence in
control over use, is better interpreted as rationalisation
mechanism typically employed in functional use of
mind-altering drugs [40]. As part of the normalisation
process, rationalising using performance enhancing
drugs with similar arguments has been evidenced previ-
ously [83–86]. Although both interpretations have aca-
demic merits and are valuable from the theoretical
point of view, the functional interpretation is able to
provide more direct and practically relevant avenues for
prevention and/or harm-reduction than the moral/
ethical argument.
The clear evidence from Internet forums for use and peo-
ple’s willingness to use ‘uncut’ DNP calls for an urgent shift
in preventive actions. Instead of efforts targeting supple-
ments and detecting contamination, the concentrated focus
should be on sales of ‘uncut’ DNP over the Internet whilst
addressing the public health concern in a more convincing
way. Preventive efforts would further benefit from research
into the most effective message framing and delivery to
discourage people from risky experimentation with un-
known and unlicensed body-image enhancing substances.
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from self-experimenting with effective appearance and
performance-enhancing drugs (such as DNP) ways of
harm-reduction should be considered. In the absence of
authoritative information on “safe use” of DNP, mainly
because such advice cannot be confidently given, online
discussion boards serve as sources of knowledge on DNP.
This is similar to the role the Internet plays in the current
drug culture [87] and related knowledge exchange [88, 89].
Although Internet forums about DNP are generally
supportive of intended users in terms of sharing experi-
ences and advising them on “safe use”, the particular
danger with DNP lies in the significant inter-individual dif-
ferences in the presence and severity of the toxic effects; as
well as in the very narrow window between effective and
toxic dose. Unlike with most novel psychoactive sub-
stances, where harm can most likely to be mitigated via ad-
vice on safe use, the combination of DNP dosage and
length of the cycle that works safely and effectively for one
may kill or seriously harm another. A harm reduction ap-
proach via providing accurate and scientifically evidenced
information highlighting the lack of established safe levels
for DNP could effectively prevent naive users playing Rus-
sian roulette with the substance. In the absence of this, the
only information source at the disposal of the interested
users is the Internet and where they can only turn to
forums and blogs for advice.
Limitations and directions for future research
The study, being the first of this type on DNP, inherently
carries several limitations. The multi-study nature of this
project did not afford more in-depth exploration of one
particular aspect but opened interesting avenues and
raised important questions for future research. In the
effort to keep the survey as succinct as possible, details
on concomitant supplement use and experience with
other ‘illegal supplements’ were not sought. A further
potential limitation here is that specific definition for
‘illegal supplements’ was not given to the participants,
thus responses to this question are influenced by the
individual interpretations what constitute illegal; and
such interpretation might had a carry-over effect on the
prevalence perception of DNP use.
Another limitation of this study is the small sample size
from gym donations for testing, which prevents us draw-
ing meaningful conclusions for the general population of
recreational or fitness exercisers. The relatively small sam-
ple of DNP users renders testing for statistically significant
differences difficult and results arising from statistical ana-
lyses should be interpreted cautiously. They are presented
to illustrate possible trends to inform future research di-
rections rather than drawing definite conclusions. For the
latter, the research should be repeated in a larger sample.
However, it must be noted that although by the generalstandards of survey methodology, the sample size may ap-
pear small; owing to the high level of suspicion that sur-
rounds any enquiry about DNP by a newcomer who is not
known in the online discussion board community, recruit-
ing 35 users is a considerable achievement which took ap-
proximately nine months. With the small sample size
limitation for quantitative analysis acknowledged, the
open-ended questions however yielded rich qualitative in-
formation from a significant cohort of DNP users on how
DNP users feel about DNP, rationalise their behavioural
choice and manage the risks that they are fully aware of.
Future studies should address the limitations of this
study whilst moving the research forward toward a better
understanding of the complexity of behavioural motiva-
tions and reasons in these distinctively different popula-
tions of DNP users. Studies focusing on people with
disordered eating and extreme dieters will make valuable
contributions, so would expanding the scope of personality
factors and situational demands. Future investigation could
also focus on the cognitive process of dealing with conflict-
ing information (i.e., DNP is very dangerous vs. DNP can
be used safely with care) in the context of weight-related
goals and past experiences, along with associated risk per-
ception, compensatory belief mechanism (particularly in
the light of the elevated risk willingness if past experience
with similar drugs are available) and trust in information
sources and purchase options. Findings from these lines of
enquiry may then be further expanded and extrapolated to
other substance categories such as stimulants, nootropics
and novel psychoactive substances (legal highs). It is
hypothesised that the customer side of the DNP market
might be similar to users of “legal highs” where the market
is not homogeneous in terms of knowledge and motiv-
ation. Distinguishing between user groups could be vital
for targeted prevention and harm reduction. Because the
majority of the DNP users reported concomitant supple-
ment use, further investigation is warranted to explore
what other substances are used while on DNP regime.
Future investigations should also explore if side effects
or severity of side effects are associated with a specific
form in which DNP was purchased. This could be an
important factor for harm-reduction but the present
study does not have sufficiently detailed information to
adequately test this hypothesis.
Our results also indicated that DNP users’ trust in
both the substance and in the quality and validity of the
information on the substance is largely based on reputa-
tion in the source. Public health authorities and regula-
tory bodies would benefit from a better understanding
of the role of trust in information in situations that carry
a degree of health-risks and transgresses social and legal
boundaries.
Although it could be argued that the majority of the
users in the present sample may not have a real need for
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centage, DNP use is not limited to this particular popula-
tion. Considerable increases in the prevalence of obesity
and diabetes flag these as global health challenges which
warrant high levels of focused research. DNP has
undoubtedly a major contribution to make for weight loss,
should the side-effect profile be controlled. A recent
report reveals that controlled-release formulation of DNP
had considerable health benefits including reversing dia-
betes but with no toxicity in rat models [90]. Further
expansion into modern formulations involving slow-
release and patch-delivery, alongside pre-dose sensitivity
tests, could place DNP within the clinicians’ arsenal to
combat obesity and some forms of diabetes; and may
reduce harm by offering a safer alternative to misusing
bulk industrial formulations or underground products.
That is not to promote a laissez fair attitude toward
DNP, or support or encourage unlicensed substance use.
Quite the contrary, we propagate a pragmatic view to
facilitate the development of evidence-based, effective
and ecologically valid prevention- and harm-reduction
strategies. A recent report by Advisory Council on the
Misuse of Drugs (ACMD) clearly showed that successful
efforts to drug- and substance use prevention are likely
to be multi-sectoral with multiple components [91].
Keeping DNP use (along with similar substances) under
control is feasible if legislation, law enforcement,
health-care, public health social marketing campaigns, au-
thorities of food- and drug safety and education work in
concert. Environmental prevention through market and
marketing controls should work in tandem with social
marketing delivering balanced and accurate information
and health-care support, including offering alternatives to
address the driving forces behind DNP use and engage in
harm-reduction where prevention is not achievable.
Stand-alone social marketing campaigns focusing on
illegality and/or danger in general terms should be avoided
as they are likely to be, at best, ineffective and may even
lead to increased interest and use. Striking the right bal-
ance between restriction of access; legal consequences of
producing, selling and using; research advances into safety
and psychosocial interventions through education which
target the underlying reasons and motives could form
positive synergy for a holistic approach and effectively
address this public health concern in a pragmatic way.
Conclusion
Contamination or adulteration with DNP may violate
labelling and manufacturing requirements for dietary
supplements but accidental ingestion, owing to the low
level found, does not appear to pose significant health
risks to the public. Public health concern however is
linked to the deliberate use and willingness to use uncut
compound despite the health warning and the lack ofcontrol that surrounds the quality and availability of this
highly dangerous substance to inexperienced or naive
users.
To mitigate health risks people willingly take with
unknown, unlicensed and potentially dangerous sub-
stances is to devise end-user-centred, proactive public
health policies. For the first time in research on DNP,
this study gave voice to the users and presents their au-
thentic view in a non-judgemental way to inform public
health policies. Off-label use of DNP is unlikely to cease
and thus realistic attempts should be made to address
the issues. Controlling efforts should focus on ‘uncut’
DNP and the Internet. In order to protect the experi-
enced and the vulnerable (inexperienced, naïve and
those suffering from eating disorders or some other rele-
vant psychological disorders), it is important to provide
accurate and trustworthy information; and acknowledge
that scare tactics may not work when ‘positive’ accounts
are readily available on the Internet. The most critical
point that social marketing information should stress is
the lack of established safe limit. Owing to the wide vari-
ation in individual sensitivity to DNP, what works for
most or many - as detailed on the Internet forums and
blogs - could be toxic or even lethal to others. For the
first time, it is a Russian roulette for every single user.
Effective prevention should even move beyond
knowledge-based intervention (such as issuing health
warnings regarding DNP) and simultaneously tackle the
motivations and tangible reasons behind the potentially
risky behaviour with unknown or unlicensed drugs and
incorporate harm-reduction measures as well as making
investment into researching a safer but equally potent
formulation. Users’ accounts leave no doubt that DNP
use can only be curbed if comparable alternatives are
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